Coping Emotionally After Skin Cancer Surgery July 18, 2025 A skin cancer diagnosis often brings with it a clear medical path—surgery, treatment, follow-up. But what’s less discussed is the…
The Cost of Sunscreen May Be Costing Lives July 1, 2025 Does Price Influence Sunscreen Use? A Closer Look at the Data The cost of sunscreen could be undermining proper usage,…
Cutaneous Squamous Cell Carcinoma is Exploding Among U.S. Males Over 65 June 7, 2025 Males over the age of 65 years are experiencing a tremendous and growing increase in nonmelanoma skin cancers, according to…
Trial Result Confirms the Advantage of Cemiplimab for Skin Cancer at High Risk of Recurrence June 3, 2025 Patients with cutaneous squamous cell carcinoma treated with cemiplimab (brand name LIBTAYO) had longer disease-free survival than patients treated with…
What’s New in Clinical Trials for Cutaneous Squamous Cell Carcinoma? May 28, 2025 Q&A with Dr. Neil D. Gross, MD, FACS Dr. Neil D. Gross, M.D., FACS, is a professor, scientist, and surgeon…
Wide Local Excision vs. Mohs Surgery: A Dermatologist Explains April 23, 2025 Introduction Dr. Yaohui (Gloria) Xu, MD, PhD, is a Professor and Section Chief of Mohs Dermatologic Surgery in the Department…
Skin Cancer Risk Persists for 30 Years after Blood Cancer Diagnosis March 31, 2025 Survivors of chronic lymphocytic leukemia and all other blood cancers need to be watchful for the signs of skin cancer,…
A Mohs Surgeon Explains the Procedure February 25, 2025 Dr. Leslie Christenson, MD, is a Dermatologist and board-certified Mohs Surgeon. Dr. Christenson practices at the McFarland Clinic in Ames,…
Checkpoint Therapeutics Receives Approval for PD-L1 Therapy December 16, 2024 The approval of cosibelimab-ipdl provides an option for patients with cutaneous squamous cell carcinoma December 13, 2024 (Sacramento, California) The…
Active Military Service Veterans are at Risk for Skin Cancers December 3, 2024 Skin Cancer Rates Among Veterans: A Closer Look at the Growing Health Risk Skin cancer is more common among U.S.…
Jun. 03, 2025 Trial Result Confirms the Advantage of Cemiplimab for Skin Cancer at High Risk of Recurrence